ClinicalTrials.Veeva

Find clinical trials for Alzheimer's Disease in Barcelona, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Alzheimer Disease
Dementia
Cognitive Dysfunction
Brain Diseases
Mental Disorders
Neurodegenerative Diseases
Psychomotor Agitation

Alzheimer's Disease trials near Barcelona, CT, ESP:

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's...

Active, not recruiting
Mild to Moderate Alzheimer's Disease
Drug: CT1812
Drug: Placebo

Phase 2

Cognition Therapeutics
Cognition Therapeutics

Barcelona, Spain and 31 other locations

and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndr...

Enrolling
Prodromal Alzheimer's Disease
Alzheimer's Disease
Biological: ACI-24.060 at Dose A
Biological: ACI-24.060 at Dose D

Phase 1, Phase 2

AC Immune

Barcelona, Spain and 16 other locations

efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with ...

Enrolling
Alzheimers Disease
Alzheimers Disease, Familial
Drug: Solanezumab
Drug: Lecanemab

Phase 2, Phase 3

The Washington University
The Washington University

Barcelona, Spain and 37 other locations

Alzheimer's disease (AD) is the most common form of dementia. In the brains of people with AD, certain small substances stick toget ...

Enrolling
Mild Cognitive Impairment Due to Alzheimer's Disease
Alzheimer's Disease, Early Onset
Drug: Placebo
Drug: PRI-002

Phase 2

PRInnovation GmbH

Barcelona, Spain and 42 other locations

To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's...

Enrolling
Alzheimers Disease
Alzheimers Disease, Familial
Drug: Lecanemab
Drug: E2814

Phase 2, Phase 3

The Washington University
The Washington University

Barcelona, Spain and 37 other locations

is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...

Enrolling
Preclinical Alzheimer's Disease
Early Preclinical Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

Phase 3

Eisai
Eisai

Barcelona, Spain and 111 other locations

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elder...

Enrolling
Alzheimer's Disease (AD)
Drug: ABBV-552
Drug: Placebo for ABBV-552

Phase 2

AbbVie
AbbVie

Sant Cugat del Vallès, Barcelona, Spain and 63 other locations

Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease...

Enrolling
Alzheimer Disease
Mild Cognitive Impairment
Drug: NIO752
Drug: Matching placebo

Phase 1

Novartis
Novartis

Barcelona, Spain and 8 other locations

versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's...

Active, not recruiting
Alzheimer's Disease
Other: Placebo
Biological: Bepranemab

Phase 2

UCB
UCB

Barcelona, Spain and 101 other locations

be from 2 clinical subgroups: mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild Alzheimer's disease...

Active, not recruiting
Alzheimer's Disease
Drug: Lecanemab 2.5 mg/kg
Drug: Lecanemab 10 mg/kg

Phase 2

Eisai
Eisai

Barcelona, Spain and 168 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems